CERELA   05438
CENTRO DE REFERENCIA PARA LACTOBACILOS
Unidad Ejecutora - UE
artículos
Título:
Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during the remission period of chemically-induced colitis
Autor/es:
DINIZ-LUERCE, T. ; GOMES SANTOS, C.A.; SANTOS ROCHAT, C.; MOREIRA, T.G.; CRUZ, D.N.; LEMOS, L.; SOUSA, A.L.; BASTOS PEREIRA, V.; AZEVEDO, M.; MORAES, K.; CARMONA CARA, D.; LEBLANC, J.G.; AZEVEDO, V.; CAETANO FARIA, A.M.; MIYOSHI, A.
Revista:
Gut Pathogens
Editorial:
BIOMED CENTRAL LTD
Referencias:
Lugar: Londres; Año: 2014 vol. 6 p. 1 - 1
ISSN:
1757-4749
Resumen:
Many probiotic bacteria have been described as a promising tool in the therapy of Inflammatory Bowel Diseases (IBD). Most of them belong to the Lactic Acid Bacteria (LAB) group, which makes part of our healthy microbiota. However, little is known about the effects of transiting dairy bacteria that make part of our diet, including Lactococcus lactis. In the present study, we analyzed the immune modulation effects of three L. lactis strains in vitro using intestinal epithelial cells and the effectiveness of a selected strain in a murine model of colitis. Only one strain, L. lactis NCDO 2118, was able to reduce the IL1-β-induced IL-8 secretion in Caco-2 cells, suggesting a potential anti-inflammatory effect of this strain. In vivo, L. lactis NCDO 2118 was administered for 4 days to C57BL/6 mice during a remission period between a first and second course of colitis induced by dextran sulfate sodium. This resulted in a milder form of recurrent colitis than observed in mice administered medium during this same period. This protective effect was not attributable to changes in secretory IgA, however NCDO 2118 administration was associated with early increase in IL-6 production and by the maintenance of IL-10 in colonic tissue. Mice fed with L. lactis NCDO 2118 increased the number of regulatory CD4+ T cells bearing surface TGF-β in the form of latency-associated protein in mesenteric lymph node and spleen. The results of this study allowed us to identify a new probiotic strain that may be used in the treatment of IBD as well as some of the mechanism involved in its anti-inflammatory effect.